The United States market has experienced a 1.4% increase over the past week and is up 17% over the last year, with earnings anticipated to grow by 15% annually in the coming years. In this favorable environment, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and demonstrate strong potential for sustained performance.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 25.17% | 38.20% | ★★★★★★ |
| Circle Internet Group | 30.81% | 60.66% | ★★★★★★ |
| Ardelyx | 20.96% | 62.26% | ★★★★★★ |
| TG Therapeutics | 26.14% | 39.04% | ★★★★★★ |
| AVITA Medical | 27.39% | 61.05% | ★★★★★★ |
| Alkami Technology | 20.57% | 76.67% | ★★★★★★ |
| Alnylam Pharmaceuticals | 24.07% | 59.30% | ★★★★★★ |
| Ascendis Pharma | 34.90% | 59.91% | ★★★★★★ |
| Caris Life Sciences | 24.80% | 72.64% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 106.24% | ★★★★★★ |
Click here to see the full list of 220 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
ADMA Biologics (ADMA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.30 billion.
Operations: The company primarily generates revenue from ADMA Biomanufacturing, contributing $449.41 million, and Plasma Collection Centers, adding $9.83 million. Its focus on plasma-derived biologics supports its operations in addressing immune deficiencies and infectious diseases across various markets.
ADMA Biologics, a firm in the biotech sector, recently showcased its robust financial health with first-quarter sales surging to $114.8 million from $81.88 million year-over-year, and net income climbing to $26.9 million from $17.81 million. This performance is underpinned by an innovative yield enhancement process approved by the U.S. FDA, which boosts production yields by about 20%. Looking ahead, ADMA has raised its revenue forecasts significantly for 2025 and 2026 to over $500 million and $625 million respectively, reflecting strong growth prospects fueled by both strategic innovations and market demand. Additionally, the company's commitment to shareholder value is evident from its recent announcement of a substantial share repurchase program valued at up to $500 million.
- Click here to discover the nuances of ADMA Biologics with our detailed analytical health report.
Explore historical data to track ADMA Biologics' performance over time in our Past section.
Alvotech (ALVO)
Simply Wall St Growth Rating: ★★★★★★
Overview: Alvotech, with a market cap of $2.99 billion, operates globally through its subsidiaries to develop and manufacture biosimilar medicines for patients.
Operations: Specializing in the biotechnology sector, Alvotech generates revenue of $587.89 million through the development and manufacture of biosimilar medicines worldwide.
Alvotech's recent strategic maneuvers, including the appointment of Linda Jónsdóttir as CFO and a significant supply agreement for its biosimilar candidate AVT10, underscore its proactive approach in the high-growth biotech sector. The company has also optimized its financial structure by renegotiating terms on a $1.08 billion loan facility, reducing interest payments by an estimated $8.2 million annually. These developments are pivotal as Alvotech prepares for the European launch of its biosimilars in Q4 2025, leveraging partnerships with major pharmaceutical entities across various global markets to enhance its commercial footprint and drive future growth.
- Take a closer look at Alvotech's potential here in our health report.
Review our historical performance report to gain insights into Alvotech's's past performance.
Exelixis (EXEL)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Exelixis, Inc. is an oncology-focused company that specializes in the discovery, development, and commercialization of new medicines for challenging cancer types in the United States, with a market capitalization of approximately $12.44 billion.
Operations: Exelixis generates revenue primarily from its biotechnology segment, amounting to approximately $2.30 billion. The company is engaged in developing and commercializing innovative cancer treatments in the U.S., targeting difficult-to-treat cancers.
Exelixis, a player in the biotech landscape, has demonstrated robust growth with a 213.9% increase in earnings over the past year, significantly outpacing its industry's growth rate of 21.7%. Forecasted to grow earnings by 19.5% annually, Exelixis surpasses the U.S. market projection of 14.9%. Recent strategic developments include positive results from the STELLAR-303 phase 3 trial and an expansion cohort of STELLAR-002 for advanced renal cell carcinoma, positioning it well within oncology-focused biotechnologies. The company's proactive R&D strategy is evident as it continues to invest heavily in innovation; R&D expenses have been strategically allocated to support these advanced trials and new drug developments, underscoring its commitment to maintaining a competitive edge through scientific advancements.
- Navigate through the intricacies of Exelixis with our comprehensive health report here.
Gain insights into Exelixis' historical performance by reviewing our past performance report.
Key Takeaways
- Reveal the 220 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if ADMA Biologics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com